Mineralys Therapeutics, Inc. (MLYS) Stock Forecast
MLYS analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 4.64 / 5 from 11 analysts
- Price target
- $46.33 average of analyst targets
- Upside to target
- +128.2% from the latest close
- Next earnings
- November 9, 2026 EPS estimate $-0.53
- 52-week range
- $20.30 – $47.33
MLYS analyst ratings
11 analystsNumber of analysts at each rating.
MLYS price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
MLYS earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.54 | −$0.60 | −$0.39 | −$0.52 | −3.7% | 8 |
| Current fiscal year (2026) | −$4.43 | −$4.63 | −$3.93 | −$2.29 | −93.6% | 8 |
| Next fiscal year (2027) | −$2.46 | −$3.78 | −$1.20 | −$4.43 | +44.6% | 9 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
MLYS revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 8 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 8 |
| Next fiscal year (2027) | $87.8M | $31.8M | $125.8M | 0.0% | 9 |
MLYS EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
MLYS revenue: reported and forecast
MLYS EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.56 | −$0.53 | −$0.53 | −$0.53 | −$0.54 | −4.3% | 4 up · 2 down |
| Current fiscal year (2026) | −$2.24 | −$4.43 | −$4.43 | −$4.43 | −$4.43 | +98.0% | 0 up · 7 down |
| Next fiscal year (2027) | −$2.10 | −$2.50 | −$2.50 | −$2.50 | −$2.46 | +17.2% | 2 up · 5 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
MLYS earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; MLYS beat in 7 of 12.
What analysts expect from MLYS
11 analysts cover Mineralys Therapeutics; their consensus rating is strong buy (4.64 on a 1–5 scale, where 5 is a strong buy). The average price target is $46.33, 128.2% above the latest close of $20.30. Analysts expect earnings of −$4.43 per share for 2026, −93.6% from a year earlier. For 2027 the average estimate is −$2.46 per share on revenue of $87.8 million. Mineralys Therapeutics beat the EPS estimate in 7 of the last 12 quarters.
Related: MLYS income statement, MLYS key metrics, MLYS chart. See the MLYS stock overview for the latest quote and news.
MLYS forecast FAQ
What is Mineralys Therapeutics's price target?
The average analyst price target for Mineralys Therapeutics is $46.33, 128.2% above the latest close of $20.30.
Is Mineralys Therapeutics a buy, hold or sell?
Of 11 analysts covering Mineralys Therapeutics, 9 rate it a strong buy, 0 a buy, 2 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Mineralys Therapeutics's EPS forecast?
Analysts forecast −$4.43 per share for 2026 (range −$4.63 to −$3.93); for 2027 the estimate is −$2.46.
When does Mineralys Therapeutics report earnings?
Mineralys Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 9, 2026; the EPS estimate is $-0.53.
Does Mineralys Therapeutics usually beat earnings estimates?
Mineralys Therapeutics reported EPS at or above the analyst estimate in 7 of the last 12 quarters.